(Q42489583)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Dario Neri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

7

Reinhard Dummer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Katharina Frey

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Kathrin Schwager

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Benedetta Belloni

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Marjam J Barysch

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

7 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

published in

Experimental Dermatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

685-688

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21649738%20AND%20SRC:MED&resulttype=core&format=json

Potent antibody therapeutics by design

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed, cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Angiotensin II activates connective tissue growth factor and induces extracellular matrix changes involving Smad/activation and p38 mitogen-activated protein kinase signalling pathways in human dermal fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

New insights into form and function of fibronectin splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Design, construction, and characterization of a large synthetic human antibody phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Tenascins: regulation and putative functions during pathological stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Fibronectin as target for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Expression of tenascin-C splice variants by human skin cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Radioimmunotherapy of brain tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Current systemic therapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Immunotherapy for advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Next generation of immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Immuno-PET: a navigator in monoclonal antibody development and applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

High response rate after intratumoral treatment with interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X

Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2011.01314.X